Anti‐ganglioside antibodies in Guillain–Barré syndrome and chronic inflammatory demyelinating polyneuropathy in Chinese patients

Fan, Chenghe; Jin, Haiqiang; Hao, Hongjun; Gao, Feng; Sun, Ying; Lu, Yuanyuan; Liu, Yuanyuan; Lv, Pu; Cui, Wei; Teng, Yuming; Huang, Yining

doi:10.1002/mus.25266

Cited by 26 publications

(28 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…When compared with AMAN, antiganglioside antibodies are not found to be associated with AIDP. 29 Antibodies to moesin, which take part in myelination, was found in patients who developed AIDP after CMV infections. On the other hand, antibodies to neurofascin were found to be shared by central/peripheral nervous system demyelinating disorders.…”

Section: Etiology and Pathophysiologymentioning

confidence: 99%

Guillain–Barre Syndrome

Malek

Salameh

2019

Semin Neurol

View full text Add to dashboard Cite

Guillain–Barre syndrome (GBS) is the leading cause of acute paralysis that can potentially affect all of the human population. GBS is believed to be an immune-mediated disease, possibly triggered by a recent infection, and driven by an immune attack targeting the peripheral nervous system. GBS can be divided into several subtypes depending on the phenotype, pathophysiology, and neurophysiological features. Unfortunately, morbidity and mortality rates are still high despite the current understanding of the pathophysiology and available treatment options. Additional research is still needed to shed more light into the pathogenesis for a better understanding and treatment of this condition.

show abstract

Section: Etiology and Pathophysiologymentioning

confidence: 99%

Guillain–Barre Syndrome

Malek

Salameh

2019

Semin Neurol

View full text Add to dashboard Cite

show abstract

“…However, Fan et al. (2017) suggested that facial nerve palsy was connected to the presence of IgM‐AGA. Only 48.3% (14/29) of patients have symptoms of a respiratory or gastrointestinal tract infection before the onset of GBS which was found in our articles, <two‐thirds described by van den Berg et al.…”

Section: Discussionmentioning

confidence: 99%

Association of anti‐gangliosides antibodies and anti‐CMV antibodies in Guillain–Barré syndrome

et al. 2017

View full text Add to dashboard Cite

IntroductionNumerous types of infection were closely related to GBS, mainly including Campylobacter jejuni, Cytomegalovirus, which may lead to the production of anti‐gangliosides antibodies (AGA). Currently, although there are increased studies on the AGA and a few studies of anti‐CMV antibodies in GBS, the association between them remains poorly documented. Therefore, our research aims to analyze the correlation of anti‐CMV antibodies and AGA in GBS.MethodsA total of 29 patients with GBS were enrolled in this study. The CMV antibodies were tested by the electrochemiluminescence immunoassay “ECLIA” (Roche Diagnostics GmbH). The serum gangliosides were determined by The EUROLINE test kit.ResultsOf the 29 patients with GBS, 9 (31%) were AGA‐seropositive, in which 22 were CMV‐IgG positive in CSF at the same time, but all 29 samples were CMV‐IgM negative in both serum and CSF. In the AGA‐positive group, the rate of both serum and CSF positive was 87.5% (7/8), higher than 50% (7/14) of the negative group, although no statistical significance was found. In addition, we found that there was a trend of higher ratio of men, a younger age onset, less frequent preceding infection, a higher level of CSF proteins, and less frequent cranial nerve deficits, although the data did not reach a statistical significance.ConclusionIn spite of no statistical significance association was found between serum AGA and CMV‐IgG in serum and CSF. However, we found that there was a trend of high positive rate of both serum and CSF‐CMV‐IgG in AGA‐positive than the negative group. So we should further expand the sample size to analyze the association between AGA and CMV or other neurotropic virus antibodies in various diseases, to observe whether they could be serological marker of these diseases (especially GBS) or the underlying pathogenesis.

show abstract

“…In these studies, IgM or IgG antibody to GM1 were detected in 0–17% or 0–23% of patients with CIDP using enzyme‐linked immunosorbent assay (ELISA) or thin layer chromatography (TLC) . In addition, recent research reports that 27.8% (5/18) or 5.6% (1/18) of patients with CIDP comprised IgM or IgG anti‐GM1 antibody . Antecedent infections are rarely observed in CIDP patients.…”

Section: Glycolipid Antibodies In Chronic Inflammatory Demyelinating mentioning

confidence: 99%

“…[56][57][58][59][60] In addition, recent research reports that 27.8% (5/18) or 5.6% (1/18) of patients with CIDP comprised IgM or IgG anti-GM1 antibody. 61 Antecedent infections are rarely observed in CIDP patients. However, Mel endez-V asquez et al reported serological evidence of C. jejuni in 10% (4/ 40) of patients with CIDP.…”

Section: Gm1 Antibodymentioning

confidence: 99%

Mechanism and spectrum of anti‐glycolipid antibody‐mediated chronic inflammatory demyelinating polyneuropathy

Kuwahara

Kusunoki

2018

Clinical & Exp Neuroim

View full text Add to dashboard Cite

The pathogenesis of chronic inflammatory demyelinating polyneuropathy (CIDP) is composed of cellular and humoral immunities. Macrophages might play a crucial role in cellular immunity. In addition, autoantibodies participate in the pathogenesis of CIDP. To date, various autoantibodies have been reported to affect peripheral nerve myelin. Although antibodies to glycolipids are frequently identified in Guillain‐Barré syndrome and closely related to the development of neuropathies, these are detected in only a small percentage of CIDP instances. Among glycolipids, sialosylneolactotetraosylceramide (LM1) is predominantly localized in human peripheral nerve myelin. LM1‐related antibodies (e.g. anti‐LM1, GM1/LM1 and GD1b/LM1 antibodies) are detected in some patients with CIDP and Guillain‐Barré syndrome. CIDP patients with those antibodies frequently present ataxia, but rarely have cranial nerve deficits; these features are associated with the localization of LM1, which is more abundant in the dorsal root than the cranial nerves. In immunoglobulin M paraproteinemic neuropathies, except for the anti‐myelin‐associated glycoprotein neuropathies, antibodies to glycolipids with disialosyl residues, such as GD1b and GQ1b, are also detected on occasion. Notably, this feature is clinically characterized by chronic ataxic neuropathy, ophthalmoplegia, immunoglobulin M paraprotein, cold agglutinins and disialosyl antibodies. Such clinical features are related to the localization of GD1b or GQ1b in human peripheral nerves. Overall, these correlations suggest a direct involvement of the antibodies in the pathogenesis of those aforementioned neuropathies.

show abstract

Anti‐ganglioside antibodies in Guillain–Barré syndrome and chronic inflammatory demyelinating polyneuropathy in Chinese patients

Abstract: These results suggest that IgG anti-GM1 antibodies are associated with AMAN, but not with AIDP, and that IgM antibodies against GM1, GM2, and GM3 are associated with facial nerve palsy. Muscle Nerve 55: 470-475, 2017.

Cited by 26 publications

References 34 publications

Guillain–Barre Syndrome

Guillain–Barre Syndrome

Association of anti‐gangliosides antibodies and anti‐CMV antibodies in Guillain–Barré syndrome

Mechanism and spectrum of anti‐glycolipid antibody‐mediated chronic inflammatory demyelinating polyneuropathy

Contact Info

Product

Resources

About